Enanta Pharmaceuticals

Blue Lake Biotechnology's pediatric nasal vaccine for RSV, BLB201, showed safety and effectiveness in a Phase I/IIa trial with no vaccine-related adverse events. Participants receiving BLB201 were over 80% less likely to contract symptomatic RSV infections compared to placebo recipients. The vaccine, administered intranasally, received FDA Fast Track designation for RSV prevention in adults and pediatric patients.

Enanta Pharmaceuticals reported positive Phase II trial results for zelicapavir, a potential RSV treatment in children aged 28 days to 36 months. The study showed a 1.2 log decline in viral load for those treated within three days of symptom onset, indicating a rapid antiviral response. Zelicapavir was well-tolerated with a favourable safety profile.

Enanta Pharmaceuticals to present topline results from Phase 2 RSVPEDs study evaluating zelicapavir for RSV in children aged 28 days to 36 months on December 9 at 8:30 a.m. ET.

Hexagon Bio appoints Yujiro Hata to its Board of Directors, leveraging his expertise in oncology to advance its pipeline of novel ADCs with next-generation natural product-based payloads for cancer treatment.

20+ companies, including Regeneron and Sanofi, are advancing 25+ urticaria drugs through clinical trials, addressing unmet needs in treatment.

DelveInsight's 'Respiratory Syncytial Virus Pipeline Insight, 2024' report details 50+ companies developing 50+ therapies, including Nirsevimab, Sisunatovir, and RSVpreF, across various stages of clinical trials. Key companies include GSK, Pfizer, and Sanofi, with recent successes like GSK's Arexvy vaccine and MSD's clesrovimab. The report covers mechanism of action, route of administration, and market dynamics.

EDP-323, an investigational RSV inhibitor, shows promising results in Phase 2a trials, potentially becoming the first antiviral drug for treating RSV infections. Early trials indicate significant reductions in viral load and symptoms, positioning EDP-323 as a breakthrough in RSV therapy.

JMP Securities' Roy Buchanan reiterates Buy rating on Enanta Pharmaceuticals (ENTA) with a $22.00 price target, citing Pfizer's discontinuation of sisunatovir and promising results from zelicapavir's pediatric trial. Buchanan also highlights EDP-323's robust impact in an RSV challenge trial, positioning Enanta favorably in the RSV therapeutic market.

Positive Phase 2a RSV human challenge trial results for Enanta's EDP-323 antiviral, conducted by hVIVO, show significant reductions in viral load and clinical symptoms, highlighting the efficacy of human challenge trials in drug development.